A novel class of broad-spectrum active-site-directed 3C-like protease inhibitors with nanomolar antiviral activity against highly immune-evasive SARS-CoV-2 Omicron subvariants

Antivirals with broad coronavirus activity are important for treating high-risk individuals exposed to the constantly evolving SARS-CoV-2 variants of concern (VOCs) as well as emerging drug-resistant variants. We developed and characterized a novel class of active-site-directed 3-chymotrypsin-like p...

Descripción completa

Detalles Bibliográficos
Autores principales: Pérez-Vargas, Jimena, Worrall, Liam J., Olmstead, Andrea D., Ton, Anh-Tien, Lee, Jaeyong, Villanueva, Ivan, Thompson, Connor A. H., Dudek, Svenja, Ennis, Siobhan, Smith, Jason R., Shapira, Tirosh, De Guzman, Joshua, Gang, Shutong, Ban, Fuqiang, Vuckovic, Marija, Bielecki, Michael, Kovacic, Suzana, Kenward, Calem, Hong, Christopher Yee, Gordon, Danielle G., Levett, Paul N., Krajden, Mel, Leduc, Richard, Boudreault, Pierre-Luc, Niikura, Masahiro, Paetzel, Mark, Young, Robert N., Cherkasov, Artem, Strynadka, Natalie C. J., Jean, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Coronaviruses
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453993/
https://www.ncbi.nlm.nih.gov/pubmed/37555275
http://dx.doi.org/10.1080/22221751.2023.2246594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453993/
https://www.ncbi.nlm.nih.gov/pubmed/37555275
http://dx.doi.org/10.1080/22221751.2023.2246594

Ejemplares similares